CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company has entered into a securities purchase agreement with certain existing and new accredited investors to issue and sell an aggregate of 25,933,706 American Depositary Shares (“ADSs”), each representing one ordinary share, and in lieu of ADSs to investors that so choose, non-voting ordinary shares, each at a price of $21.42 per share, through a private investment in public equity (“PIPE”) financing.

英国剑桥和波士顿——（商业新闻短讯）——Bicycle Therapeutics plc（纳斯达克代码：BCYC）是一家基于其专有双环肽（Bicycle®）技术开创新型差异化治疗药物的制药公司，今天宣布，该公司已与某些现有和新的合格投资者签订了证券购买协议，通过私募股权投资（“PIPE”）融资，发行和出售总计25933706股美国存托股（“ADS”），每股代表一股普通股，代替ADS，向选择无投票权普通股的投资者发行和出售，每股价格为21.42美元。

Bicycle anticipates the gross proceeds from the PIPE to be approximately $555 million. The financing is expected to close on May 28, 2024, subject to customary closing conditions..

Bicycle预计该管道的总收益约为5.55亿美元。根据惯例的交割条件，预计融资将于2024年5月28日结束。。

The financing was led by a U.S.-based healthcare focused investor with participation from Deep Track Capital, EcoR1 Capital, Fairmount, Forbion, Perceptive Advisors and RA Capital Management. Bicycle plans to use the net proceeds to fund the continued development of its proprietary pipeline and for other research and development, as well as for general corporate purposes..

此次融资由一位以美国医疗保健为重点的投资者牵头，来自Deep Track Capital、EcoR1 Capital、Fairmount、Forbion、Perceptive Advisors和RA Capital Management。Bicycle计划将净收益用于资助其专有管道的持续开发、其他研发以及一般企业用途。。

“We are excited to announce today’s financing as it underscores the increasing conviction that our investors have in the Bicycle® platform and team to create novel precision-guided therapeutics, which we believe have the potential to offer patients a significantly improved quality of life over other treatments,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics.

Bicycle therapeutics首席执行官凯文·李（KevinLee）博士说：“我们很高兴宣布今天的融资，因为它强调了我们的投资者对Bicycle®平台和团队创造新型精确引导疗法的信心日益增强，我们相信这有可能为患者提供比其他疗法更显着改善的生活质量。”。

“This financing will support our progress across multiple high-value programs and earlier discovery pipeline, both of which have multiple catalysts in the second half of 2024, as we develop innovative medicines that could help patients with cancer and other diseases live longer and live well.”.

“这笔资金将支持我们在多个高价值项目和早期发现渠道方面取得进展，这两个项目在2024年下半年都有多种催化剂，因为我们开发的创新药物可以帮助癌症和其他疾病患者活得更长，活得更好。”。

Subsequent to the closing of this financing, Bicycle expects its pro forma cash and cash equivalents will be approximately $1.0 billion as of May 23, 2024. This cash estimate is a preliminary estimate and based on information currently available to management, and these estimates could change.

在此次融资结束后，Bicycle预计截至2024年5月23日，其形式现金和现金等价物将约为10亿美元。该现金估算是一个初步估算，基于管理层目前可获得的信息，这些估算可能会发生变化。

Jefferies is acting as sole placement agent for the financing.

Jefferies是此次融资的独家配售代理。

The offer and sale of the securities to be sold in the PIPE are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws, and will be sold in a private placement pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission (“SEC”) under the Securities Act.

拟在管道中出售的证券的发售和出售是在不涉及公开发售的交易中进行的，并且这些证券尚未根据经修订的《1933年证券法》（“证券法”）或适用的州证券法进行登记，并将根据《证券法》第4（a）（2）节和证券交易委员会（“SEC”）根据《证券法》颁布的D条例第506条以私募方式出售。

Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Pursuant to the securities purchase agreement, Bicycle has agreed to file a registration statement with the SEC registering the resale of the ADSs and ordinary shares or ADSs issued upon the re-designation of the non-voting ordinary shares issued in the PIPE..

因此，除非根据有效的登记声明或《证券法》登记要求的适用豁免，否则不得在美国发售或出售证券。根据《证券购买协议》，Bicycle已同意向SEC提交一份登记声明，登记美国存托股和普通股的转售，或在重新指定管道中发行的无投票权普通股后发行的美国存托股。。

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或招揽购买要约，也不构成在根据任何州或司法管辖区的证券法律注册或资格之前，在任何州或司法管辖区出售这些证券是非法的。。

About Bicycle Therapeutics

关于自行车疗法

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry.

Bicycle Therapeutics是一家临床阶段的制药公司，开发了一类新型药物，称为Bicycle®分子，用于治疗现有疗法服务不足的疾病。自行车分子是完全合成的短肽，受小分子支架的约束，形成两个稳定其结构几何形状的环。

This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials.

这种限制促进了具有高亲和力和选择性的靶标结合，使自行车分子成为药物开发的有吸引力的候选物。该公司正在评估BT8009，一种靶向Nectin-4（一种经过充分验证的肿瘤抗原）的Bicycle®毒素缀合物（BTC®）；BT5528是一种针对EphA2的BTC，EphA2是一种历史上不可药用的靶标；和BT7480，一种靶向Nectin-4和激动CD137的自行车肿瘤靶向免疫细胞激动剂®（Bicycle-TICA®），在公司赞助的临床试验中。

Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology..

此外，该公司正在开发用于放射性药物的Bicycle®放射性结合物（BRC™），并通过各种合作伙伴关系，探索使用Bicycle®技术开发肿瘤以外疾病的治疗方法。。

Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass.

Bicycle Therapeutics总部位于英国剑桥，其领导团队的许多关键职能和成员位于马萨诸塞州剑桥。

Forward Looking Statements

前瞻性声明

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipates,” “could,” “expects,” “may,” “plans,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words.

本新闻稿可能包含根据1995年《私人证券诉讼改革法案》安全港条款所作的前瞻性声明。这些陈述可以用“预期”、“可能”、“预期”、“可能”、“计划”、“潜在”、“寻求”、“将”等词语以及这些词语的变体或旨在识别前瞻性陈述的类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Certain statements contained in this press release, including those relating to the timing and completion of the financing and the satisfaction of customary closing conditions related to the financing, the anticipated total gross proceeds from the financing, the planned use of proceeds of the financing and Bicycle’s expected financial runway following the financing, are forward‐looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward‐looking statements.

本新闻稿中包含的某些声明，包括与融资的时间和完成以及与融资相关的惯例交割条件的满足、融资的预期总收益、融资收益的计划使用以及融资后自行车的预期财务跑道有关的声明，都是前瞻性声明，涉及许多风险和不确定性，可能导致实际结果与前瞻性声明中的结果存在重大差异。

These risks and uncertainties include, but are not limited to, risks and uncertainties associated with the consummation of the proposed financing, the completion of the financing on the anticipated terms or at all, uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed financing, the risk that Bicycle’s projections regarding its expected cash runway are inaccurate or that its conduct of its business requires more cash than anticipated and general economic conditions.

这些风险和不确定性包括但不限于与完成拟议融资相关的风险和不确定性、按预期条款完成融资或完全融资、与市场条件相关的不确定性、满足与拟议融资相关的惯例交割条件、Bicycle对其预期现金跑道的预测不准确或其业务开展需要比预期和一般经济条件更多现金的风险。

Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Other factors that may cause actual results to differ fr.

自行车可能无法真正实现这些前瞻性声明中披露的计划、意图或期望，您不应过度依赖这些前瞻性声明。可能导致实际结果不同的其他因素。